Compare Stocks: AMLX, SMMT, EXEL, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.78B	-0.13	1.91 million shs	2.05 million shs
BMRN BioMarin Pharmaceutical	$63.94 -1.8%	$63.83	$49.26 ▼ $70.98	$12.60B	0.24	1.69 million shs	4.46 million shs
EXEL Exelixis	$58.36 -0.2%	$55.44	$33.76 ▼ $59.72	$14.49B	0.42	1.94 million shs	5.24 million shs
SMMT Summit Therapeutics	$17.85 +0.7%	$14.71	$12.07 ▼ $29.23	$14.14B	-1.24	5.98 million shs	13.06 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.51%	+2.50%	-16.04%	+106.83%	+153.80%
BMRN BioMarin Pharmaceutical	-1.75%	-2.65%	-7.77%	+16.91%	+17.60%
EXEL Exelixis	-0.22%	+3.99%	+7.30%	+12.43%	+44.31%
SMMT Summit Therapeutics	+0.73%	+1.71%	+36.16%	+29.82%	-1.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.78B	-0.13	1.91 million shs	2.05 million shs
BMRN BioMarin Pharmaceutical	$63.94 -1.8%	$63.83	$49.26 ▼ $70.98	$12.60B	0.24	1.69 million shs	4.46 million shs
EXEL Exelixis	$58.36 -0.2%	$55.44	$33.76 ▼ $59.72	$14.49B	0.42	1.94 million shs	5.24 million shs
SMMT Summit Therapeutics	$17.85 +0.7%	$14.71	$12.07 ▼ $29.23	$14.14B	-1.24	5.98 million shs	13.06 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.51%	+2.50%	-16.04%	+106.83%	+153.80%
BMRN BioMarin Pharmaceutical	-1.75%	-2.65%	-7.77%	+16.91%	+17.60%
EXEL Exelixis	-0.22%	+3.99%	+7.30%	+12.43%	+44.31%
SMMT Summit Therapeutics	+0.73%	+1.71%	+36.16%	+29.82%	-1.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	19.89% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$89.17	39.46% Upside
EXEL Exelixis	2.35	Hold	$50.29	-13.84% Downside
SMMT Summit Therapeutics	2.47	Hold	$25.91	45.14% Upside

Current Analyst Ratings Breakdown

Latest AMLX, SMMT, EXEL, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/11/2026	EXEL Exelixis	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$60.00
9/9/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/8/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$33.00
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/1/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	41.33	N/A	N/A	$2.78 per share	11.66
BMRN BioMarin Pharmaceutical	$3.22B	3.84	$2.80 per share	22.81	$31.68 per share	2.02
EXEL Exelixis	$2.32B	6.23	$3.02 per share	19.32	$8.06 per share	7.24
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	172.81	11.73	0.47	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.35	15.69	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest AMLX, SMMT, EXEL, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

AMLX, SMMT, EXEL, and BMRN Headlines

Recent News About These Companies

Summit Therapeutics: It's Okay Not To Have An Answer

September 17 at 9:32 AM | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)

September 15, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?

September 15, 2026 | marketbeat.com

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15, 2026 | businesswire.com

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

September 13, 2026 | streetinsider.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...

September 13, 2026 | streetinsider.com

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

September 13, 2026 | msn.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

September 13, 2026 | gurufocus.com

September 13, 2026 | businesswire.com

Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT

September 12, 2026 | marketbeat.com

Summit Therapeutics PLC (SMMT)

September 10, 2026 | fr.investing.com

Summit Therapeutics Shares Rise After Upgrade From Jefferies

September 9, 2026 | marketscreener.comM

Summit Therapeutics shares gain after Jefferies upgrades stock to buy

September 9, 2026 | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?

September 9, 2026 | marketbeat.com

Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP

September 9, 2026 | marketbeat.com

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

September 8, 2026 | insidermonkey.com

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

September 7, 2026 | insidermonkey.com

Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen

September 5, 2026 | marketbeat.com

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

September 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, SMMT, EXEL, and BMRN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$32.41 -1.53 (-4.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$33.18 +0.78 (+2.39%)

As of 09/18/2026 07:53 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

BioMarin Pharmaceutical NASDAQ:BMRN

$63.94 -1.14 (-1.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$63.90 -0.04 (-0.06%)

As of 09/18/2026 07:30 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$58.36 -0.13 (-0.22%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$58.74 +0.38 (+0.66%)

As of 09/18/2026 07:30 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics NASDAQ:SMMT

$17.85 +0.13 (+0.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.79 -0.06 (-0.32%)

As of 09/18/2026 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, SMMT, EXEL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, SMMT, EXEL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, SMMT, EXEL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, SMMT, EXEL, and BMRN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, SMMT, EXEL, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, SMMT, EXEL, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, SMMT, EXEL, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX, SMMT, EXEL, and BMRN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools